Raltegravir

Synonym(e)

MK-0518; RGV

Antiretroviral wirksamer Wirkstoff zur Behandlung der HIV-Infektion. Hemmer der HIV-Integrase (Strangtransfer-Inhibitor).

2mal/Tag 400 mg p.o. angewendet. Eine Boosterung mit Ritonavir ist nicht erforderlich.

Dermatologie

Morbilliformes, varizelliformes Exanthem bei Coxsackie-Virus-Infektion.

Selten Übelkeit, Schwindel, Kopfschmerzen, Diarrhoen und Fieber. Aufgrund der Studienlage sind keine Langzeitdaten verfügbar.

Isentress

Jones J et al. (2007) Advances in antiretroviral therapy. Top HIV Med 15: 48-82
Kassahun K et al. (2007) Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 35: 1657-1663
Lataillade M, Kozal MJ (2006) The hunt for HIV-1 integrase inhibitors. AIDS Patient Care STDS 20: 489-501
Lataillade M, Chiarella J, Kozal MJ (2007) Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther 12: 563-570
Markowitz M et al. (2007) Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 46: 125-133
Petitjean G et al. (2007) Unintegrated HIV-1 provides an inducible and functional reservoir in untreated and highly active antiretroviral therapy-treated patients. Retrovirology 4: 60
Stellbrink HJ (2007) Antiviral Drugs in the Treatment of AIDS: What is in the Pipeline? Eur J Med Res 12: 483-495